Compare Amgen, Inc. (AMGN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Novartis AG — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| AMGN | NVS | |
|---|---|---|
Market Cap | $224.14B | $295.37B |
Sector | Health | Health |
52-Week High | $417.20 | $168.62 |
52-Week Low | $271.18 | $119.31 |
Enterprise Value | $267.45B | $336.69B |
Dividend Yield | 2.43% | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
